Stock Taper 
ASP Isotopes Inc., a pre-commercial advanced materials company based in Boca Raton, Florida, develops and sells isotopes like Molybdenum-100, Carbon-14, Silicon-28, and Uranium-235 for medical, scientific, and energy industries.
ASP Isotopes produces a key precursor isotope for Lutetium-177, a vital medical radioisotope for targeted cancer therapies, marking its debut in commercial production for the growing nuclear medicine market.
In late 2025, ASP Isotopes Inc. received critical regulatory approvals for its acquisition of Renergen Limited, a strategic move to combine its isotope enrichment technology with Renergen's helium and natural gas assets. This event was a significant step towards creating a combined entity focused on producing critical materials for high-tech sectors like semiconductors and clean energy, culminating in the deal's closure in early 2026.
ASP Isotopes finalized its acquisition of Renergen Limited, a producer of liquefied helium and natural gas. This transformative deal creates a vertically integrated global supplier of critical materials, combining ASPi's advanced isotope enrichment technologies with Renergen's helium and natural gas operations in South Africa.
ASP Isotopes Inc. (NASDAQ: ASPI - Get Free Report) Director John Ryan acquired 15,000 shares of ASP Isotopes stock in a transaction that occurred on Wednesday, September 30th. The shares were purchased at an average cost of $2.68 per share, for a total transaction of $40,200.00. Following the purchase, the director directly owned 675,222 shares in
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 SCL | $62.46 | COMPARE |
 ODC | $86.08 | COMPARE |
 GPRE | $15.09 | COMPARE |
 CMP | $22.95 | COMPARE |
 GSM | $4.18 | COMPARE |
 WLKP | $21.28 | COMPARE |
 BAK | $1.85 | COMPARE |
 TROX | $3.79 | COMPARE |
